Nothing Special   »   [go: up one dir, main page]

WO1999004026A3 - Lentiviral vectors - Google Patents

Lentiviral vectors Download PDF

Info

Publication number
WO1999004026A3
WO1999004026A3 PCT/US1998/014996 US9814996W WO9904026A3 WO 1999004026 A3 WO1999004026 A3 WO 1999004026A3 US 9814996 W US9814996 W US 9814996W WO 9904026 A3 WO9904026 A3 WO 9904026A3
Authority
WO
WIPO (PCT)
Prior art keywords
lentiviral
lentiviral vectors
ltr
lentiviral vector
rre
Prior art date
Application number
PCT/US1998/014996
Other languages
French (fr)
Other versions
WO1999004026A2 (en
Inventor
Shin-Tai Chen
Mehdi Gasmi
Jiing Kuan Yee
Douglas J Jolly
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to JP2000503232A priority Critical patent/JP2001510053A/en
Priority to EP98936923A priority patent/EP1003894A2/en
Priority to CA002296319A priority patent/CA2296319A1/en
Priority to AU85762/98A priority patent/AU8576298A/en
Publication of WO1999004026A2 publication Critical patent/WO1999004026A2/en
Publication of WO1999004026A3 publication Critical patent/WO1999004026A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Lentiviral vectors are provided comprising a 5' lentiviral LTR, a tRNA binding site, a packaging signal, a promoter operably linked to one or more genes of interest, an origin of second strand DNA synthesis and a 3' lentiviral LTR, wherein the lentiviral vector contains a nuclear transport element that is not RRE. Also provided are expression cassettes and packaging cell lines for producing lentiviral vector particles.
PCT/US1998/014996 1997-07-18 1998-07-20 Lentiviral vectors WO1999004026A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000503232A JP2001510053A (en) 1997-07-18 1998-07-20 Lentivirus vector
EP98936923A EP1003894A2 (en) 1997-07-18 1998-07-20 Lentiviral vectors
CA002296319A CA2296319A1 (en) 1997-07-18 1998-07-20 Lentiviral vectors
AU85762/98A AU8576298A (en) 1997-07-18 1998-07-20 Lentiviral vectors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5306697P 1997-07-18 1997-07-18
US60/053,066 1997-07-18

Publications (2)

Publication Number Publication Date
WO1999004026A2 WO1999004026A2 (en) 1999-01-28
WO1999004026A3 true WO1999004026A3 (en) 1999-04-08

Family

ID=21981716

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/014996 WO1999004026A2 (en) 1997-07-18 1998-07-20 Lentiviral vectors

Country Status (5)

Country Link
EP (1) EP1003894A2 (en)
JP (1) JP2001510053A (en)
AU (1) AU8576298A (en)
CA (1) CA2296319A1 (en)
WO (1) WO1999004026A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107949424B (en) * 2015-03-20 2022-03-01 天普大学-联邦高等教育系统 TAT-induced CRISPR/endonuclease-based gene editing

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531123B1 (en) 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
WO2000000600A2 (en) * 1997-09-22 2000-01-06 Chang Lung Ji Lentiviral vectors, comprising modified major donor splice sites and major packaging signals
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
JP2002508338A (en) * 1997-12-12 2002-03-19 ナルディニ，ルイジ Therapeutic use of lentiviral vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1045921A2 (en) * 1998-01-16 2000-10-25 Chiron Corporation Feline immunodeficiency virus gene therapy vectors
US6492166B1 (en) 1998-07-29 2002-12-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of constitutive transport elements for host range control
JP2003530301A (en) 1999-04-15 2003-10-14 ウェルスタット バイオロジクス コーポレイション Treatment of neoplasms with viruses
EP1173551A2 (en) * 1999-04-23 2002-01-23 Centre for Translational Research in Cancer Pseudotyped retroviral vector for gene therapy of cancer
JP4979851B2 (en) * 1999-04-29 2012-07-18 ジービーピー アイピー リミテッド ライアビリティ カンパニー High titer and safe production method
US6730297B1 (en) 1999-05-28 2004-05-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
EP1183383B1 (en) * 1999-06-09 2006-10-18 Cambridge University Technical Services Limited Siv-based packaging-deficient vectors
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
AU2001278430A1 (en) * 2000-05-22 2001-12-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Systemic and cardiovascular transduction with lentiviral vectors
AU2001265190A1 (en) * 2000-05-30 2001-12-11 University Of Rochester Siv derived lentiviral vector systems
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
WO2002092134A1 (en) 2001-05-14 2002-11-21 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
AU2002327412A1 (en) 2001-08-02 2003-02-17 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
KR20040054699A (en) 2001-10-02 2004-06-25 엥스띠뛰 끌레이톤 드 라 러쉐르쉬 Methods and compositions relating to restricted expression lentiviral vectors and their applications
JP4800924B2 (en) 2003-03-07 2011-10-26 ロバーツ リサーチ インスティテュート Use of myxoma virus for therapeutic treatment of cancer and chronic viral infections
JP2007505130A (en) * 2003-09-09 2007-03-08 バイレクシス コーポレイション Lentiviral vector-based approach for generating an immune response against HIV in humans
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
NZ577283A (en) 2005-03-07 2010-11-26 Robarts Res Inst Use of a Myxoma virus that does not express functional M135R
EP3031923A1 (en) 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
US20180094280A1 (en) * 2015-03-20 2018-04-05 Bluebird Bio, Inc. Vector formulations
US11597917B2 (en) 2017-07-06 2023-03-07 The Medical College Of Wisconsin, Inc. In vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders
MA53020A (en) * 2018-05-18 2021-05-05 Zhengzhou Gensciences Inc ENHANCED FVIII FUSION PROTEIN AND ASSOCIATED USE
US20210348192A1 (en) * 2018-09-20 2021-11-11 National University Corporation Tokyo Medical And Dental University Method for increasing lentiviral vector production

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031602A1 (en) * 1995-04-01 1996-10-10 Oxford Biomedica (Uk) Limited Retroviral vectors
US5585263A (en) * 1994-05-20 1996-12-17 University Of Alabama At Birmingham Research Foundation Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV
WO1997012622A1 (en) * 1995-10-06 1997-04-10 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997020052A1 (en) * 1995-11-28 1997-06-05 Clinical Technologies, Inc. Recombinant hiv and modified packaging cells and method for treating acquired immune deficiency syndrome

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585263A (en) * 1994-05-20 1996-12-17 University Of Alabama At Birmingham Research Foundation Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV
WO1996031602A1 (en) * 1995-04-01 1996-10-10 Oxford Biomedica (Uk) Limited Retroviral vectors
WO1997012622A1 (en) * 1995-10-06 1997-04-10 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997020052A1 (en) * 1995-11-28 1997-06-05 Clinical Technologies, Inc. Recombinant hiv and modified packaging cells and method for treating acquired immune deficiency syndrome

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BENDER M. A. ET AL.: "EVIDENCE THAT THE PACKAGING SIGNAL OF MOLONEY MURINE LEUKEMIA VIRUS EXTENDS INTO THE GAG REGION", JOURNAL OF VIROLOGY, vol. 61, no. 5, 19 May 1987 (1987-05-19), pages 1639 - 1646, XP002036903 *
BRAY M. ET AL.: "A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type I expression and replication Rev-independent.", PROC. NATL. ACAD. SCI. USA, vol. 91, 1994 - 1256, pages 1260, XP002092484 *
HUANG J. AND LIANG T. J.: "A novel hepatitis B virus (HBV) genetic element with Rev response element-like properties that is essential for expression of HBV gene products.", MOLECULAR AND CELLULAR BIOLOGY, vol. 13, no. 12, 1993, pages 7476 - 7486, XP000676652 *
LEVINE F. ET AL.: "Efficient gene expression in mammalian cells from a dicistronic transcriptional unit in an improved retroviral vector.", GENE, vol. 108, 1991, pages 167 - 174, XP002092486 *
MORGAN R. A. ET AL: "RETROVIRAL VECTORS CONTAINING PUTATIVE INTERNAL RIBOSOME ENTRY SITES: DEVELOPMENT OF A POLYCISTRONIC GENE TRANSFER SYSTEM AND APPLICATIONS TO HUMAN GENE THERAPY", NUCLEIC ACIDS RESEARCH, vol. 20, no. 6, 1992, pages 1293 - 1299, XP002037514 *
NALDINI L. ET AL.: "IN VIVO GENE DELIVERY AND STABLE TRANSDUCTION OF NONDIVIDING CELLS BY A LENTIVIRAL VECTOR", SCIENCE, vol. 272, no. 5259, 12 April 1996 (1996-04-12), pages 263 - 267, XP000583652 *
ORY D. S. ET AL.: "A STABLE HUMAN-DERIVED PACKAGING CELL LINE FOR PRODUCTION OF HIGH TITER RETROVIRUS/VESICULAR STOMATITIS VIRUS G PSEUDOTYPES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 93, October 1996 (1996-10-01), pages 11400 - 11406, XP002030784 *
SRINIVASAKUMAR N. ET AL.: "The effect of viral regulatory protein expression on gene delivery by human immundeficiency virus type I vectors produced in stable packaging cell lines.", JOURNAL OF VIROLOGY, vol. 71, no. 8, August 1997 (1997-08-01), pages 5841 - 5848, XP002092487 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107949424B (en) * 2015-03-20 2022-03-01 天普大学-联邦高等教育系统 TAT-induced CRISPR/endonuclease-based gene editing

Also Published As

Publication number Publication date
CA2296319A1 (en) 1999-01-28
AU8576298A (en) 1999-02-10
WO1999004026A2 (en) 1999-01-28
JP2001510053A (en) 2001-07-31
EP1003894A2 (en) 2000-05-31

Similar Documents

Publication Publication Date Title
WO1999004026A3 (en) Lentiviral vectors
WO1995030763A3 (en) Retroviral vectors having a reduced recombination rate
AU2998597A (en) Crossless retroviral vectors
EP1285967A3 (en) Human retroviral packaging cell line
AU4951293A (en) Synthesis of manganese bleach catalyst
WO1999036511A3 (en) Feline immunodeficiency virus gene therapy vectors
CA2170509A1 (en) Dna encoding prostaglandin receptor ep2
AU7332198A (en) Lentivirus based vector and vector system
CA2165954A1 (en) Prostaglandin receptor fp and dna encoding it
WO2000000600A3 (en) Lentiviral vectors, comprising modified major donor splice sites and major packaging signals
AU5669680A (en) Reformed rice product
CA2211204A1 (en) Prostaglandin receptor dp
AU2997295A (en) Composite membrane for chemical synthesis
ZA966711B (en) Chemical synthesis.
AU4158597A (en) Countercurrent reaction vessel
AU1998297A (en) Nucleic acid constructs containing genes encoding transport signals
AU6139699A (en) Packaging cell lines for hiv-derived retroviral vector particles
AU2352095A (en) 7-fluoro-2, 3-didehydrosialic acid and intermediate for synthesis thereof
AU4766596A (en) Ob gene product antibodies
WO1997008190A3 (en) Compounds
AU697289B2 (en) Photoprotective cosmetic compositions containing TIO2 nanopigments and an acylamino acid
AU6180896A (en) Improved synthesis of 2,4,6,8,10,12-hexabenzyl-2,4,6,8,10,12-hexaazatetracyclo{5.5 .0.05,9.03,11}dodecane
AU1246399A (en) Vectors inhibiting or delaying the binding of an immunodeficiency vi rus to cells
AU1504695A (en) Synthesis gas preparation by partial oxidation-steam reforming
WO1995017418A3 (en) NOVEL INTERMEDIATES FOR THE SYNTHESIS OF L-ASPARTYL-D-α-AMINOALKANOYL-(S)-N-α-ALKYLBENZYL AMIDES USEFUL AS ARTIFICIAL SWEETENERS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2296319

Country of ref document: CA

Ref country code: CA

Ref document number: 2296319

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998936923

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 85762/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998936923

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998936923

Country of ref document: EP